Matthew Biegler
Stock Analyst at Oppenheimer
(0.84)
# 3,692
Out of 4,829 analysts
76
Total ratings
24.24%
Success rate
-19.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $5.08 | +136.22% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $0.15 | +5,187.51% | 7 | Mar 21, 2025 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 → $25 | $4.60 | +443.48% | 5 | Mar 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $6.61 | +580.79% | 4 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $96.91 | +18.67% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $17.42 | +204.25% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $10.10 | +226.73% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $1.23 | +1,526.02% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $3.00 | - | 6 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $1.16 | +848.28% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $97.17 | +28.64% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $9.91 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.36 | +161.19% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $5.49 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.04 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.45 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.16 | +2,055.17% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.93 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.67 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $8.18 | +4,300.98% | 1 | Nov 30, 2022 |
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $5.08
Upside: +136.22%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.15
Upside: +5,187.51%
Olema Pharmaceuticals
Mar 19, 2025
Reiterates: Outperform
Price Target: $30 → $25
Current: $4.60
Upside: +443.48%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $6.61
Upside: +580.79%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $96.91
Upside: +18.67%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $17.42
Upside: +204.25%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.10
Upside: +226.73%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.23
Upside: +1,526.02%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.00
Upside: -
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $1.16
Upside: +848.28%
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $97.17
Upside: +28.64%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $9.91
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $5.36
Upside: +161.19%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $5.49
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.04
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.45
Upside: -
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $1.16
Upside: +2,055.17%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.93
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.67
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $8.18
Upside: +4,300.98%